Modulation of the Osteosarcoma Expression Phenotype by MicroRNAs

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Namløs, Heidi M ^a   Meza Zepeda, Leonardo A ^a,b   Barøy, Tale ^a   Østensen, Ingrid H G ^a,b   Kresse, Stine H ^a   Kuijjer, Marieke L ^a,c   Serra, Massimo ^a,d   Bürger, Horst ^a,e   Cleton Jansen, Anne Marie ^a,c   Myklebost, Ola ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^e UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 1; MICRORNA 106A; MICRORNA 106B; MICRORNA 126; MICRORNA 130; MICRORNA 133A; MICRORNA 133B; MICRORNA 142; MICRORNA 144; MICRORNA 150; MICRORNA 17; MICRORNA 195; MICRORNA 196A; MICRORNA 196B; MICRORNA 206; MICRORNA 21; MICRORNA 223; MICRORNA 301; MICRORNA 31; MICRORNA 374A; MICRORNA 451; MICRORNA 486; MICRORNA 497; MICRORNA 9; MICRORNA 92A; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P85; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; ENZYME SUBUNIT; GENE CLUSTER; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; OSTEOBLAST; OSTEOSARCOMA; PARALOGY; PATHOGENESIS; PHENOTYPE;

BONE NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOSARCOMA; PHENOTYPE; REAL-TIME POLYMERASE CHAIN REACTION; RNA; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84868110139     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048086     Document Type: Article

References (60)

1. Friedman RC, Farh KK, Burge CB, Bartel DP, (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19: 92-105.
2. Bartel DP, (2009) MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233.
3. Subramanian S, Lui WO, Lee CH, Espinosa I, Nielsen TO, et al. (2007) MicroRNA expression signature of human sarcomas. Oncogene 27: 2015-2026.
4. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al. (2005) MicroRNA expression profiles classify human cancers. Nature 435: 834-838.
5. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103: 2257-2261.
6. PosthumaDeBoer J, Witlox MA, Kaspers GJ, van Royen BJ, (2011) Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. Clin Exp Metastasis 28: 493-503.
7. Raymond AK, Ayala AG, Knuutila S (2002) Conventional osteosarcoma. In: Fletcher CDM, Unni KK, Mertens F, editors. World Health Organization Classification of Tumours Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press.
8. Maire G, Martin JW, Yoshimoto M, Chilton-MacNeill S, Zielenska M, et al. (2011) Analysis of miRNA-gene expression-genomic profiles reveals complex mechanisms of microRNA deregulation in osteosarcoma. Cancer Genetics 204: 138-146.
9. Baumhoer D, Zillmer S, Unger K, Rosemann M, Atkinson MJ, et al. (2012) MicroRNA profiling with correlation to gene expression revealed the oncogenic miR-17-92 cluster to be up-regulated in osteosarcoma. Cancer Genetics 205: 212-219.
10. Jones KB, Salah Z, Del Mare S, Galasso M, Gaudio E, et al. (2012) miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res 72: 1865-1877.
11. Lulla RR, Costa FF, Bischof JM, Chou PM, de FBM, et al. (2011) Identification of Differentially Expressed MicroRNAs in Osteosarcoma. Sarcoma 2011: 732690.
12. Thayanithy V, Sarver AL, Kartha RV, Li L, Angstadt AY, et al. (2011) Perturbation of 14q32 miRNAs-cMYC gene network in osteosarcoma. Bone 50: 171-181.
13. Osaki M, Takeshita F, Sugimoto Y, Kosaka N, Yamamoto Y, et al. (2011) MicroRNA-143 Regulates Human Osteosarcoma Metastasis by Regulating Matrix Metalloprotease-13 Expression. Mol Ther 19: 1123-1130.
14. Zhang H, Cai X, Wang Y, Tang H, Tong D, et al. (2010) microRNA-143, down-regulated in osteosarcoma, promotes apoptosis and suppresses tumorigenicity by targeting Bcl-2. Oncol Rep 24: 1363-1369.
15. Ziyan W, Shuhua Y, Xiufang W, Xiaoyun L, (2010) MicroRNA-21 is involved in osteosarcoma cell invasion and migration. Medical Oncology 28: 1469-1474.
16. Sarver AL, Phalak R, Thayanithy V, Subramanian S (2010) S-MED: Sarcoma microRNA Expression Database. Lab Invest.
17. Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, et al. (2010) Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer 49: 40-51.
18. Buddingh EP, Kuijjer ML, Duim RA, Burger H, Agelopoulos K, et al. (2011) Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage-activating agents. Clin Cancer Res 17: 2110-2119.
19. Kuijjer ML, Namlos HM, Hauben EI, Machado I, Kresse SH, et al. (2011) mRNA expression profiles of primary high-grade central osteosarcoma are preserved in cell lines and xenografts. BMC Med Genomics 4: 66.
20. Lin SM, Du P, Huber W, Kibbe WA, (2008) Model-based variance-stabilizing transformation for Illumina microarray data. Nucleic Acids Res 36: e11.
21. (2005) R: A language and environment for statistical computing, reference index version 2.9.0. Vienna, Austria: R Foundation for Statistical Computing.
22. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80.
23. Du P, Kibbe WA, Lin SM, (2008) lumi: a pipeline for processing Illumina microarray. Bioinformatics 24: 1547-1548.
24. Simes RJ, (1986) An improved Bonferroni procedure for multiple tests of significance. Biometrika 73: 751-754.
25. Ruepp A, Kowarsch A, Schmidl D, Buggenthin F, Brauner B, et al. (2010) PhenomiR: a knowledgebase for microRNA expression in diseases and biological processes. Genome Biol 11: R6.
26. Kresse SH, Rydbeck H, Skårn M, Namløs HM, Barragan-Polania AH, et al. (2012) Integrative Analysis Reveals Relationships of Genetic and Epigenetic Alterations in Osteosarcoma. PLoS ONE In Press.
27. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT, (2005) c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435: 839-843.
28. Sylvestre Y, De Guire V, Querido E, Mukhopadhyay UK, Bourdeau V, et al. (2007) An E2F/miR-20a Autoregulatory Feedback Loop. J Biol Chem 282: 2135-2143.
29. Woods K, Thomson JM, Hammond SM, (2007) Direct Regulation of an Oncogenic Micro-RNA Cluster by E2F Transcription Factors. J Biol Chem 282: 2130-2134.
30. Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, et al. (2008) E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 13: 272-286.
31. Kuijjer ML, Rydbeck H, Kresse SH, Buddingh EP, Lid AB, et al. (2012) Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data. Genes, Chromosomes and Cancer 51: 696-706.
32. Mohseny AB, Machado I, Cai Y, Schaefer KL, Serra M, et al. (2011) Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. Lab Invest 91: 1195-1205.
33. Mohseny AB, Hogendoorn PC, (2011) Concise review: mesenchymal tumors: when stem cells go mad. Stem Cells 29: 397-403.
34. Bianchi N, Zuccato C, Finotti A, Lampronti I, Borgatti M, et al. (2012) Involvement of miRNA in erythroid differentiation. Epigenomics 4: 51-65.
35. Vasilatou D, Papageorgiou S, Pappa V, Papageorgiou E, Dervenoulas J, (2010) The role of microRNAs in normal and malignant hematopoiesis. Eur J Haematol 84: 1-16.
36. Watanabe A, Tagawa H, Yamashita J, Teshima K, Nara M, et al. (2011) The role of microRNA-150 as a tumor suppressor in malignant lymphoma. Leukemia 25: 1324-1334.
37. Kobayashi E, Hornicek FJ, Duan Z, (2012) MicroRNA Involvement in Osteosarcoma. Sarcoma 2012: 359739.
38. Datta J, Kutay H, Nasser MW, Nuovo GJ, Wang B, et al. (2008) Methylation Mediated Silencing of MicroRNA-1 Gene and Its Role in Hepatocellular Carcinogenesis. Cancer Research 68: 5049-5058.
39. Li D, Zhao Y, Liu C, Chen X, Qi Y, et al. (2011) Analysis of MiR-195 and MiR-497 Expression, Regulation and Role in Breast Cancer. Clinical Cancer Research 17: 1722-1730.
40. Meister J, Schmidt MH, (2010) miR-126 and miR-126*: new players in cancer. ScientificWorldJournal 10: 2090-2100.
41. Navon R, Wang H, Steinfeld I, Tsalenko A, Ben-Dor A, et al. (2009) Novel rank-based statistical methods reveal microRNAs with differential expression in multiple cancer types. PLoS One 4: e8003.
42. Wong QWL, Lung RWM, Law PTY, Lai PBS, Chan KYY, et al. (2008) MicroRNA-223 Is Commonly Repressed in Hepatocellular Carcinoma and Potentiates Expression of Stathmin1. Gastroenterology 135: 257-269.
43. Wang W, Peng B, Wang D, Ma X, Jiang D, et al. (2010) Human tumor MicroRNA signatures derived from large-scale oligonucleotide microarray datasets. Int J Cancer 129: 1624-1634.
44. Li Z, Hassan MQ, Volinia S, van Wijnen AJ, Stein JL, et al. (2008) A microRNA signature for a BMP2-induced osteoblast lineage commitment program. Proc Natl Acad Sci U S A 105: 13906-13911.
45. Maruyama Z, Yoshida CA, Furuichi T, Amizuka N, Ito M, et al. (2007) Runx2 determines bone maturity and turnover rate in postnatal bone development and is involved in bone loss in estrogen deficiency. Developmental Dynamics 236: 1876-1890.
46. Sadikovic B, Yoshimoto M, Chilton-Macneill S, Thorner P, Squire JA, et al. (2009) Identification of Interactive Networks of Gene Expression Associated with Osteosarcoma Oncogenesis by Integrated Molecular Profiling. Hum Mol Genet 18: 1962-1975.
47. Kurek KC, Del Mare S, Salah Z, Abdeen S, Sadiq H, et al. (2010) Frequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increased tumorigenicity and aberrant RUNX2 expression. Cancer Res 70: 5577-5586.
48. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, et al. (2005) A microRNA polycistron as a potential human oncogene. Nature 435: 828-833.
49. de Pontual L, Yao E, Callier P, Faivre L, Drouin V, et al. (2011) Germline deletion of the miR-17 approximately 92 cluster causes skeletal and growth defects in humans. Nat Genet 43: 1026-1030.
50. Liao M, Jiang W, Chen X, Lian B, Li W, et al. (2010) Systematic analysis of regulation and functions of co-expressed microRNAs in humans. Mol Biosyst 6: 1863-1872.
51. Petrocca F, Vecchione A, Croce CM, (2008) Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling. Cancer Res 68: 8191-8194.
52. Mestdagh P, Boström A-K, Impens F, Fredlund E, Van Peer G, et al. (2011) The miR-17-92 MicroRNA Cluster Regulates Multiple Components of the TGF-[beta] Pathway in Neuroblastoma. Molecular Cell 40: 762-773.
53. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, et al. (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065-7070.
54. Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, et al. (2010) Identification of the miR-106b~25 MicroRNA Cluster as a Proto-Oncogenic PTEN-Targeting Intron That Cooperates with Its Host Gene MCM7 in Transformation. Sci Signal 3: ra29.
55. Huse JT, Brennan C, Hambardzumyan D, Wee B, Pena J, et al. (2009) The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev 23: 1327-1337.
56. Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, et al. (2009) miR-19 is a key oncogenic component of mir-17-92. Genes Dev 23: 2839-2849.
57. Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, et al. (2008) Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 9: 405-414.
58. Park SY, Lee JH, Ha M, Nam JW, Kim VN, (2009) miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol 16: 23-29.
59. Wang Y, Chen A, Guo F, Xia Y, (2008) Expression and clinical significance of PTEN protein in osteosarcoma. The Chinese-German Journal of Clinical Oncology 7: 296-299.
60. Salmena L, Carracedo A, Pandolfi PP, (2008) Tenets of PTEN tumor suppression. Cell 133: 403-414.